NextCure (NASDAQ:NXTC – Get Free Report) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect NextCure to announce earnings of ($1.98) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.
NextCure (NASDAQ:NXTC – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, analysts expect NextCure to post $-8 EPS for the current fiscal year and $-8 EPS for the next fiscal year.
NextCure Stock Down 7.4%
NextCure stock opened at $5.02 on Thursday. The company has a market capitalization of $18.12 million, a PE ratio of -0.29 and a beta of 1.42. NextCure has a 12-month low of $1.55 and a 12-month high of $15.74. The firm’s fifty day moving average is $3.66 and its 200 day moving average is $8.77.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on NXTC
Insider Activity
In other NextCure news, major shareholder Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock in a transaction that occurred on Monday, July 27th. The stock was acquired at an average price of $5.00 per share, with a total value of $38,990.00. Following the transaction, the insider owned 383,456 shares in the company, valued at $1,917,280. This trade represents a 2.08% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders acquired 17,608 shares of company stock valued at $87,720. 11.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new position in shares of NextCure in the fourth quarter valued at $160,000. Millennium Management LLC bought a new stake in shares of NextCure during the fourth quarter worth about $185,000. Geode Capital Management LLC raised its holdings in shares of NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in NextCure in the 4th quarter valued at about $988,000. Institutional investors and hedge funds own 42.65% of the company’s stock.
About NextCure
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
Read More
- Five stocks we like better than NextCure
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
